Direct oral anticoagulants are an effective and safe alternative to warfarin treatment for patients with nonvalvular atrial fibrillation and hyperthyroidism.
Hypothyroidism, hyperglycemia, and low adrenocorticotrophic hormone levels are associated with lower bone mass in patients with thalassemia major.
Tepezza™, an insulin-like growth factor-1 receptor inhibitor, is expected to be available in the coming weeks.
In patients with hyperthyroidism, treatment with radioiodine is not associated with incident cancer in long-term follow-up.
Compared with patients with transient congenital hypothyroidism, patients with permanent disease were on a higher levothyroxine dose at discontinuation.
In the case of hypothyroidism, Hashimoto thyroiditis is the most common autoimmune presentation.
From 2009 to 2016, the incidence of thyroid cancer reached a plateau and possibly started to decline.
While the rate of thyroid dysfunction among patients with psoriasis generally is not higher than expected, psoriasis in patients with thyroid dysfunction is more clinically severe and serum levels of C-reactive protein are higher.
Maternal TSH levels >4 mIU/L are associated with increased risks for prematurity and neonatal respiratory distress syndrome.
Hypothyroidism is significantly associated with increased all-cause mortality, but not cardiovascular mortality, among the elderly.
The Food and Drug Administration (FDA)’s Dermatologic and Ophthalmic Drugs Advisory Committee voted in favor of the approval of teprotumumab (Horizon Therapeutics) for the treatment of thyroid eye disease.